UPTAKE OF NEWER SECOND-LINE DIABETES MEDICATIONS IN REAL-WORLD VULNERABLE POPULATIONS

被引:0
|
作者
Ogunsanmi, D. [1 ]
Harrison, A. T. [2 ]
Kovesdy, C. P. [1 ]
Surbhi, S. [1 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USA
[2] Rhodes Coll, Memphis, TN 38112 USA
关键词
D O I
暂无
中图分类号
F [经济];
学科分类号
02 ;
摘要
HSD112
引用
收藏
页码:S499 / S499
页数:1
相关论文
共 50 条
  • [31] Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study
    Montvida, Olga
    Shaw, Jonathan E.
    Blonde, Lawrence
    Paul, Sanjoy K.
    DIABETES OBESITY & METABOLISM, 2018, 20 (07): : 1722 - 1731
  • [32] PATIENT PREFERENCES FOR SECOND-LINE MEDICATIONS TO MANAGE TYPE 2 DIABETES MELLITUS
    Ozdemir, Semra
    Baid, Drishti
    Verghese, Naina
    Lam, Amanda Yun Rui
    Lee, Phong Ching
    Ying, Lim Adoree Yi
    Zhu, Ling
    Finkelstein, Eric A.
    Goh, Su-Yen
    MEDICAL DECISION MAKING, 2020, 40 (01) : E286 - E287
  • [33] A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic
    Church, Matt
    Taylor, Paul
    Summers, Yvonne
    Califano, Raffaele
    Rafee, Shereen
    Dixon, Mairead
    Clarke, Lisa
    Cove-Smith, Laura
    LUNG CANCER, 2021, 156 : S31 - S31
  • [34] Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
    Cuker, Adam
    Buckley, Brian
    Mousseau, Marie-Catherine
    Barve, Aditya Anand
    Haenig, Jens
    Bussel, James B.
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2051 - 2058
  • [35] First and second-line palliative systemic treatment outcomes in a real-world metastatic pancreatic cancer cohort
    Pijnappel, E.
    Dijksterhuis, W. P. M.
    van der Geest, L.
    de vos-Geelen, J.
    de Groot, J. W. B.
    ten Tije, A. J.
    Homs, M.
    Creemers, G-J.
    Mohammad, N. Haj
    van Laarhoven, H. W. M.
    Wilmink, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S939 - S940
  • [36] Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma
    Ahn, Daniel
    Sidel, Michelle
    Panattoni, Laura
    Sacks, Naomi
    Hernandez, Jennifer
    Villacorta, Reginald
    FUTURE ONCOLOGY, 2022, 18 (30) : 3419 - 3433
  • [37] Real-world Positioning and Effectiveness of First- and Second-Line Biological Therapy in Inflammatory Bowel Diseases
    Reves, Joana
    Torres, Joana
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (06): : 787 - 789
  • [38] Real-world outcomes with lurbinectedin in second-line and beyond for small cell lung cancer in Korea.
    Shim, Joosung Gabriel
    Lim, Sun Min
    Cho, Byoung Chul
    Hong, Min Hee
    Lee, Jii Bum
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 211 - 211
  • [39] The efficacy of second-line chemotherapy in the management of classic and iatrogenic Kaposi sarcoma: An analysis of real-world data
    Khanmammadov, Nijat
    Ferhatoglu, Ferhat
    Paksoy, Nail
    Dogan, Izzet
    Khishigsuren, Bayarmaa
    Nizam, Nihan
    Saip, Pinar
    Aydiner, Adnan
    MEDICINE, 2025, 104 (06)
  • [40] Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
    Maria Di Bartolomeo
    Monica Niger
    Giuseppe Tirino
    Angelica Petrillo
    Rosa Berenato
    Maria Maddalena Laterza
    Filippo Pietrantonio
    Federica Morano
    Maria Antista
    Sara Lonardi
    Lorenzo Fornaro
    Stefano Tamberi
    Elisa Giommoni
    Alberto Zaniboni
    Lorenza Rimassa
    Gianluca Tomasello
    Teodoro Sava
    Massimiliano Spada
    Tiziana Latiano
    Alessandro Bittoni
    Alessandro Bertolini
    Ilaria Proserpio
    Katia Bruna Bencardino
    Francesco Graziano
    Giordano Beretta
    Salvatore Galdy
    Jole Ventriglia
    Simone Scagnoli
    Andrea Spallanzani
    Raffaella Longarini
    Ferdinando De Vita
    Targeted Oncology, 2018, 13 : 227 - 234